Paper Details

  1. Home
  2. Paper Details

Clinical overview of the seizure risk of dalfampridine.

Author: BienenE Jay, HautSheryl R, MillerAaron

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Dalfampridine extended release tablets are approved for the improvement of walking in patients with multiple sclerosis (MS). Its mechanism of action and narrow therapeutic range necessitate the evaluation of seizure risk in treated patients.
Paper Details　
Original Abstract of the Article :
Dalfampridine extended release tablets (dalfampridine-ER; known as prolonged-, modified or sustained-release fampridine in some countries) is a potassium channel blocker approved at 10 mg taken every 12 h, for the improvement of walking in patients with multiple sclerosis (MS). This has been demonst...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/14740338.2012.697896

データ提供：米国国立医学図書館（NLM）

Dalfampridine: Navigating the Tightrope of Benefit and Risk

The field of [neurology and multiple sclerosis (MS) research] is a dynamic one, where researchers strive to improve the lives of individuals living with this chronic autoimmune disease. This research explores the potential benefits and risks of dalfampridine, a medication approved to improve walking in patients with MS. The study focuses on the potential for seizures, a known side effect of this medication, and highlights the importance of careful monitoring and management.

The Double-Edged Sword of Treatment

The study acknowledges that while dalfampridine can improve walking speed, it also carries a risk of seizures. This highlights the delicate balance between potential benefits and risks associated with medication. Think of it as navigating a tightrope over a vast desert, where the potential for reward comes with a risk of falling. Careful monitoring and management are essential for maximizing the benefits of dalfampridine while minimizing the risk of seizures.

A Balancing Act of Benefits and Risks

This research underscores the importance of a comprehensive understanding of medication benefits and risks, allowing healthcare providers to make informed decisions about treatment. It's a reminder that the journey to managing MS can be complex and require a careful balancing act between potential benefits and potential risks. Think of it as a desert journey, where careful navigation and informed decision-making are essential for reaching the oasis of health.

Dr.Camel's Conclusion

This research highlights the importance of careful monitoring and management of dalfampridine, a medication that offers potential benefits for walking in patients with MS but also carries a risk of seizures. It's a reminder that the journey to managing MS can be complex, requiring a careful balancing act between potential benefits and potential risks.

Date :
  1. Date Completed 2012-10-30
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22703551

DOI: Digital Object Identifier

10.1517/14740338.2012.697896

Related Literature

Article Analysis
・Effects of dalfampridine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.